Predict your next investment

Angelini Pharma company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
angelinipharma.com

See what CB Insights has to offer

Partners & Customers

5

Service Providers

1

About Angelini Pharma

Angelini Pharma develops pharmaceuticals for mental health conditions, pain & inflammation, paediatric diseases, and consumer health. The company also partners with hospitals, research centers, pharma biotech, and CROs to favor innovation.

Angelini Pharma Headquarter Location

Viale Amelia 70

Roma, 00181,

Italy

+39 06 78053-1

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Angelini Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Angelini Pharma Rank

Latest Angelini Pharma News

Mental health crisis – a ticking time bomb. [Promoted content]

Oct 4, 2021

This year’s Olympics games grabbed attention beyond the marvellous display of athletic feats. Celebrated gymnast Simon Bile’s decision to pull out of this year’s games to focus on her mental health made headlines across the globe. Her inspirational move proved to be a turning point in destigmatising mental health issues in the athletic world. Following Bile’s example, American sprinter Noah Lyles, women’s pole vault silver medallist Anzhelika Sidorova and Spanish heptathlete Maria Vicente bravely opened up about their own mental health struggles, sparking a long-overdue discussion on a topic too often swept under the carpet. According to studies, one out of six people in Europe are afflicted with mental health conditions. Mental illnesses are among the top ten most common non-communicable diseases. The devastating socio-economic effects of the COVID-19 outbreak has further triggered a global mental health crisis. Since the pandemic took hold in 2020, the anxiety and stress levels of people across the globe have skyrocketed. In a recent study, 40 percent of people reported that COVID-19 has had a negative effect on their mental health. The pandemic has also exacerbated gender-related challenges with its mental health consequences disproportionately affecting women, both at work and at home. According to recent estimates, 83 percent of women report that the pandemic negatively impacted their mental health compared to 36 percent of men. Pregnant women, women in the postpartum period, or those experiencing trauma such as a miscarriage or abuse from intimate partners, were found to be most susceptible to the psychological impacts of the pandemic. The burden of household chores and childcare also had a significant impact on women’s mental well-being with 44 percent of women with children under 12 years of age reported they were struggling with household responsibilities as compared to just 20 percent men. A healthy population is the cornerstone of a thriving and prosperous economy. However, according to the latest estimates, 70 percent of the employed population in Europe suffer from mild to moderate mental health conditions. Mental illness also has a significant impact on people’s ability to work, limiting their capacity to participate in the labour market. Studies show that employment rates among people with severe mental disorders were as low as 45-55 percent. The high episodes of absenteeism and presenteeism among people suffering from mental health also results in high costs to the employers’ equivalent to the 1.6 percent of European GDP in loss in labour productivity. The COVID outbreak is further expected to worsen the economic impact of mental health, especially among youth and people from lower socio-economic status. This further underlines the urgency for addressing the unfurling mental health crisis. With the surge in the number of mental health cases among the workforce, employers have a key role to play in plugging the gaps and responding to the mental health needs of the workforce. Since its inception fifty years ago, Angelini Pharma has been committed to improving people’s mental health and well-being. Recognising the urgent need for addressing the bubbling mental health crisis in Europe, Angelini Pharma in partnership with The European House Ambrosetti launched Headway in 2017. A multi-disciplinary platform for knowledge exchange, Headway, aims to prevent, diagnose, and find innovative solutions to reduce the burden of mental health and the associated stigma. The initiative was designed to complement the existing programmes of the World Health Organisation by encouraging strategic reflection and analysis of mental health management across Europe. It brought together over 40 experts from the medical and scientific community and representatives from patient and family health organisations to spark debate and discussion on best practices for addressing mental health issues. On October 7, ahead of the world mental health day on October 10, Headway 20233 will be launching a holistic mental health index for Europe providing a comprehensive overview of the state of mental health and response systems at workplace, schools, and society. By presenting a detailed country-wise analysis of gaps and best practices across Europe, the report is intended to serve as a guide for governments and organisations to mitigate mental health issues. Despite the debilitating impacts of the pandemic, it presents us with an opportunity to address the ticking mental health crisis. As we build back our economies and societies from the ravages of COVID-19, it is vital to put mental health at the heart of recovery efforts. We must all wake up to the mental health emergency and put mental well-being on top of the public health agenda.

Angelini Pharma Acquisitions

4 Acquisitions

Angelini Pharma acquired 4 companies. Their latest acquisition was Arvelle Therapeutics on January 04, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/4/2021

Series A - II

$991

$207.8M

Acquired

18

4/24/2020

Subscribe to see more

$991

$99M

Subscribe to see more

10

3/10/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2021

4/24/2020

3/10/2020

3/9/2020

Investment Stage

Series A - II

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$207.8M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

18

10

10

10

Angelini Pharma Partners & Customers

5 Partners and customers

Angelini Pharma has 5 strategic partners and customers. Angelini Pharma recently partnered with TrueBlue on March 3, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

3/10/2021

Vendor

TrueBlue

United States

Angelini Pharma Chooses AiDEA’s Artificial Intelligence to Boost Its Digital Transformation and International Growth

VERONA , Italy -- -- Trueblue , a leading provider of AI solutions for Operational and Analytical CRM in the Life Science industry announces that Angelini Pharma , as part of a major global digital transformation process , has chosen AiDEA , the first AI-Digital Cloud Pharma CRM solution based on Microsoft 365 .

2

7/26/2020

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/13/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/12/2020

Distributor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/11/2019

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/10/2021

7/26/2020

7/13/2020

4/12/2020

7/11/2019

Type

Vendor

Vendor

Licensor

Distributor

Vendor

Business Partner

TrueBlue

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Angelini Pharma Chooses AiDEA’s Artificial Intelligence to Boost Its Digital Transformation and International Growth

VERONA , Italy -- -- Trueblue , a leading provider of AI solutions for Operational and Analytical CRM in the Life Science industry announces that Angelini Pharma , as part of a major global digital transformation process , has chosen AiDEA , the first AI-Digital Cloud Pharma CRM solution based on Microsoft 365 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Angelini Pharma Service Providers

1 Service Provider

Angelini Pharma has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Service Provider

Associated Rounds

Acquired

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Angelini Pharma Team

2 Team Members

Angelini Pharma has 2 team members, including current Chief Executive Officer, Pierluigi Antonelli.

Name

Work History

Title

Status

Pierluigi Antonelli

Chief Executive Officer

Current

Fabio De Luca

Chiesi Farmaceutici, Chiesi Farmaceutici SpA, Pfizer, Bristol-Myers Squibb, and Abbott

Chief Marketing Officer

Current

Name

Pierluigi Antonelli

Fabio De Luca

Work History

Chiesi Farmaceutici, Chiesi Farmaceutici SpA, Pfizer, Bristol-Myers Squibb, and Abbott

Title

Chief Executive Officer

Chief Marketing Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.